Vivos Therapeutics Announces Strategic Collaboration with Multi-Location Florida Cardiology Group to Expand Sleep Apnea and Insomnia Services
Key Points of the Report
- Collaboration Agreement: Vivos Therapeutics, Inc. (NASDAQ: VVOS) has entered into a collaboration agreement with South Palm Cardiovascular Associates, LLC (SPCVA), a well-established, multi-location Florida cardiology practice with approximately 30,000 patients.
- Formation of AIM Florida, LLC: The partnership supports the creation of AIM Florida, LLC, a physician-aligned management services organization. AIM Florida aims to expand integrated diagnostic and therapeutic clinical treatment services for cardiovascular disease (CVD) patients in Florida who also suffer from obstructive sleep apnea (OSA) and insomnia.
- Ownership Structure: Vivos expects to hold at least 80% of the membership interests in AIM Florida, with SPCVA holding up to 20%. This structure is subject to definitive documentation and regulatory requirements.
- Scalable, Compliant Model: The collaboration is designed to be scalable and compliant, serving as a potential template for expansion to over 2,500 similar cardiology groups nationwide.
- Financial Impact: The operational plan anticipates the initial deployment of a fully staffed Sleep Optimization Team serving about 250 patients per month, generating over \$6 million annually with contribution margins approaching 50% once fully operational. Additional teams may be added to meet growing demand.
- Strategic Advantage: Unlike prior models requiring acquisitions, this partnership involves direct collaboration with the medical community, minimizing capital outlays and aligning interests.
- Focus Area: Initial focus will be in Palm Beach County, with plans for further expansion within Florida and potentially across the U.S.
- Regulatory Compliance: The collaboration will comply with all relevant federal and state healthcare regulations, including the Anti-Kickback Statute and physician self-referral rules. All clinical decisions will remain strictly under the authority of licensed healthcare providers.
- Forward-Looking Statements: The company highlights that the collaboration is subject to negotiation and execution of definitive agreements, and there is no assurance that AIM Florida will be formed or achieve anticipated results.
Investor-Relevant Details and Potential Price-Sensitive Information
- Potential Revenue Growth: If successful, this model could contribute substantially to Vivos’ cash flow and profitability, with the pilot operation targeting \$6 million in annual revenue per team at attractive contribution margins.
- Expansion Potential: The company’s intention to replicate this model with other physician groups and specialties could significantly broaden Vivos’ commercial footprint, supporting long-term growth.
- Execution Risk: The press release emphasizes that definitive agreements are not yet signed, and the collaboration’s financial and operational benefits remain subject to execution and regulatory clearance.
- Regulatory and Market Risks: There are explicit cautions regarding regulatory compliance, the possibility that AIM Florida may not be formed, and other risks such as capital access, reimbursement challenges, and the company’s ability to maintain its Nasdaq listing.
- Product Differentiation: Vivos’ FDA-cleared Complete Airway Repositioning and Expansion (CARE) devices are the only ones cleared for treating severe OSA in adults and moderate-to-severe OSA in children, which sets the company apart in the sleep apnea market.
- OSA Market Opportunity: OSA affects over 1 billion people globally, with the vast majority undiagnosed, indicating a large addressable market.
- Potential Share Price Impact: Successful implementation and scaling of this collaboration could materially improve Vivos’ financial performance, making this announcement potentially share price sensitive.
Comprehensive Details for Investors
Vivos Therapeutics, Inc. has announced a strategic collaboration with South Palm Cardiovascular Associates, a multi-location Florida cardiology practice. This partnership aims to form AIM Florida, LLC, which will integrate sleep apnea and insomnia diagnostics and treatments into cardiovascular care settings. The model leverages Vivos’ prior experience in Las Vegas and is designed to be scalable, compliant, and capital-light compared to traditional acquisition strategies.
The collaboration is expected to address a major clinical challenge, as OSA is independently linked with increased cardiovascular risk and mortality, especially among patients with moderate-to-severe disease. SPCVA cardiologists have voiced longstanding concerns about the national shortage of board-certified sleep medicine specialists, resulting in delayed diagnosis and treatment. AIM Florida aims to fill this gap, initially serving Palm Beach County, and plans to expand further.
Financially, Vivos projects that a single Sleep Optimization Team could generate more than \$6 million per year with contribution margins near 50%, once fully established. The model is designed for scalability, with the potential for additional teams and expansion to other practices and communities.
Importantly, the collaboration will operate under strict compliance with all healthcare regulations, with clinical decisions remaining solely under the direction of licensed providers. The company has emphasized that execution risk remains, as definitive agreements have yet to be signed and regulatory processes must be completed.
This initiative is part of Vivos’ broader mission to provide innovative, non-surgical, and non-pharmaceutical treatments for OSA and related conditions, leveraging its unique FDA-cleared technologies. If successful, the collaboration could materially impact Vivos’ revenues, profitability, and long-term growth trajectory, making this a potentially significant development for shareholders.
Disclaimer
This article contains forward-looking statements based on current information and assumptions, including expectations regarding the collaboration between Vivos Therapeutics and SPCVA, anticipated operational and financial impacts, and regulatory compliance. Actual results may differ materially due to a variety of risks and uncertainties, including finalization of definitive agreements, regulatory and market risks, and operational execution. Investors should review the company’s filings with the SEC for additional risk factors. This article is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities.
